Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rBCG-N-RSV vaccine
- Development stage
- Phase 2
- Lead developer
- Biothervax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
rBCG-N-RSV is a recombinant live-attenuated vaccine candidate developed by Biothervax SpA in collaboration with the Pontificia Universidad Católica de Chile. It utilizes the Mycobacterium bovis Bacillus Calmette-Guérin (BCG) strain as a bacterial vector to express the nucleoprotein (N) of the Respiratory Syncytial Virus (RSV). This approach is designed to induce a robust, Th1-polarized cellular immune response against RSV, which is intended to provide protection without the risk of vaccine-enhanced respiratory disease (ERD) associated with Th2-biased responses. As it is based on the BCG vaccine, it also maintains the potential to protect against tuberculosis. The vaccine is currently being evaluated in Phase 2 clinical trials for the prevention of RSV infection in adults aged 60 and older, and has previously undergone testing in pediatric populations.
- Other names
- recombinant BCG-N-RSV vaccine
02
Targets
RSV N (Respiratory syncytial virus nucleoprotein)
Beyond the preview
Go deeper on rBCG-N-RSV vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rBCG-N-RSV vaccine.